fda warning letters compounding semaglutide september 2025 and Novo Nordisk Warned of GLP-1 Telehealth Takedown. What's Next? FDA Drug Recalls and Warnings:

The current MDL, established in February 2024, involves claims against Novo Nordisk alleging failure to warn patients about severe gastrointestinal complications including gastroparesis and vision loss from non-arteritic anterior ischemic optic neuropathy (NAION)

[1] [2] Marketed under brand names including Ozempic, Wegovy, and Rybelsus, semaglutide works by mimicking the action of the naturally occurring incretin hormone GLP-1

Timeline: Week 1-2 post-GLP-1 : Ghrelin rebounds, food noise returns most noticeably Week 3-6 : Body is recalibrating

Patients who want a baseline can upload existing labs to the portal or order an at-home lab kit at their own expense (roughly $175$250)